Which has preferable valuation and earnings, SEPN or EOLS?

Septerna has higher earnings, but lower revenue than Evolus. Septerna is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Septerna $45.95M 32.46 -$48.88M -$0.81 N/A Evolus $297.18M 1.28 -$51.64M -$0.67 N/A

Is SEPN or EOLS more profitable?

Evolus has a net margin of -14.39% compared to Septerna's net margin of -49.88%. Evolus' return on equity of 0.00% beat Septerna's return on equity. Company Net Margins Return on Equity Return on Assets Septerna -49.88% -12.72% -8.87% Evolus -14.39% N/A -19.03%

Do analysts recommend NNNN or EOLS?

Evolus has a consensus target price of $16.00, indicating a potential upside of 178.02%. Given Evolus' stronger consensus rating and higher probable upside, analysts plainly believe Evolus is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Evolus 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, NNNN or EOLS?

Anbio Biotechnology has higher earnings, but lower revenue than Evolus. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 156.28 $6.40M N/A N/A Evolus $297.18M 1.28 -$51.64M -$0.67 N/A

Is NNNN or EOLS more profitable?

Anbio Biotechnology has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Company Net Margins Return on Equity Return on Assets Anbio Biotechnology N/A N/A N/A Evolus -14.39% N/A -19.03%

Which has better earnings and valuation, AKTS or EOLS?

Evolus has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aktis Oncology $6.50M 203.37 -$63.73M -$0.38 N/A Evolus $297.18M 1.28 -$51.64M -$0.67 N/A

Is AKTS or EOLS more profitable?

Aktis Oncology has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Evolus -14.39% N/A -19.03%

Evolus (EOLS) Competitors

$5.76 +0.21 (+3.69%)

As of 12:44 PM Eastern

Compare

EOLS vs. SEPN, MLTX, NNNN, PAHC, and AKTS

Should you buy Evolus stock or one of its competitors? MarketBeat compares Evolus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evolus include Septerna (SEPN), MoonLake Immunotherapeutics (MLTX), Anbio Biotechnology (NNNN), Phibro Animal Health (PAHC), and Aktis Oncology (AKTS). These companies are all part of the "pharmaceutical products" industry.

How does Evolus compare to Septerna?

Septerna (NASDAQ:SEPN) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Septerna currently has a consensus target price of $45.89, suggesting a potential upside of 38.68%. Evolus has a consensus target price of $16.00, suggesting a potential upside of 178.02%. Given Evolus' higher probable upside, analysts clearly believe Evolus is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Evolus has a net margin of -14.39% compared to Septerna's net margin of -49.88%. Evolus' return on equity of 0.00% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Evolus	-14.39%	N/A	-19.03%

Septerna has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market. Comparatively, Evolus has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

90.7% of Evolus shares are owned by institutional investors. 5.8% of Septerna shares are owned by company insiders. Comparatively, 5.0% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Septerna has higher earnings, but lower revenue than Evolus. Septerna is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	32.46	-$48.88M	-$0.81	N/A
Evolus	$297.18M	1.28	-$51.64M	-$0.67	N/A

In the previous week, Septerna had 2 more articles in the media than Evolus. MarketBeat recorded 2 mentions for Septerna and 0 mentions for Evolus. Septerna's average media sentiment score of 0.37 beat Evolus' score of 0.00 indicating that Septerna is being referred to more favorably in the media.

Company	Overall Sentiment
Septerna	Neutral
Evolus	Neutral

Summary

Septerna beats Evolus on 10 of the 17 factors compared between the two stocks.

How does Evolus compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

In the previous week, MoonLake Immunotherapeutics had 5 more articles in the media than Evolus. MarketBeat recorded 5 mentions for MoonLake Immunotherapeutics and 0 mentions for Evolus. MoonLake Immunotherapeutics' average media sentiment score of 0.39 beat Evolus' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MoonLake Immunotherapeutics	Neutral
Evolus	Neutral

Evolus has higher revenue and earnings than MoonLake Immunotherapeutics. Evolus is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Evolus	$297.18M	1.28	-$51.64M	-$0.67	N/A

MoonLake Immunotherapeutics presently has a consensus target price of $24.21, indicating a potential upside of 24.66%. Evolus has a consensus target price of $16.00, indicating a potential upside of 178.02%. Given Evolus' stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 5.0% of Evolus shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Evolus	-14.39%	N/A	-19.03%

MoonLake Immunotherapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Evolus has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

Summary

Evolus beats MoonLake Immunotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Evolus compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Evolus (NASDAQ:EOLS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Anbio Biotechnology has a net margin of 0.00% compared to Evolus' net margin of -14.39%.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Evolus	-14.39%	N/A	-19.03%

90.7% of Evolus shares are held by institutional investors. 5.0% of Evolus shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Evolus has a consensus target price of $16.00, indicating a potential upside of 178.02%. Given Evolus' stronger consensus rating and higher probable upside, analysts plainly believe Evolus is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Anbio Biotechnology's average media sentiment score of 0.00 equaled Evolus'average media sentiment score.

Company	Overall Sentiment
Anbio Biotechnology	Neutral
Evolus	Neutral

Anbio Biotechnology has higher earnings, but lower revenue than Evolus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	156.28	$6.40M	N/A	N/A
Evolus	$297.18M	1.28	-$51.64M	-$0.67	N/A

Anbio Biotechnology has a beta of 5.15, suggesting that its share price is 415% more volatile than the broader market. Comparatively, Evolus has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

Summary

Evolus beats Anbio Biotechnology on 6 of the 11 factors compared between the two stocks.

How does Evolus compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Phibro Animal Health has a net margin of 6.35% compared to Evolus' net margin of -14.39%. Phibro Animal Health's return on equity of 37.14% beat Evolus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Evolus	-14.39%	N/A	-19.03%

Phibro Animal Health has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Evolus has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market.

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Phibro Animal Health had 3 more articles in the media than Evolus. MarketBeat recorded 3 mentions for Phibro Animal Health and 0 mentions for Evolus. Phibro Animal Health's average media sentiment score of 1.52 beat Evolus' score of 0.00 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Overall Sentiment
Phibro Animal Health	Very Positive
Evolus	Neutral

Phibro Animal Health has higher revenue and earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.50B	0.90	$48.26M	$2.33	14.32
Evolus	$297.18M	1.28	-$51.64M	-$0.67	N/A

Phibro Animal Health presently has a consensus target price of $42.50, suggesting a potential upside of 27.41%. Evolus has a consensus target price of $16.00, suggesting a potential upside of 178.02%. Given Evolus' stronger consensus rating and higher possible upside, analysts plainly believe Evolus is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Phibro Animal Health beats Evolus on 11 of the 16 factors compared between the two stocks.

How does Evolus compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Evolus (NASDAQ:EOLS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

Aktis Oncology currently has a consensus price target of $34.60, indicating a potential upside of 39.77%. Evolus has a consensus price target of $16.00, indicating a potential upside of 178.02%. Given Evolus' higher possible upside, analysts plainly believe Evolus is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Aktis Oncology had 2 more articles in the media than Evolus. MarketBeat recorded 2 mentions for Aktis Oncology and 0 mentions for Evolus. Aktis Oncology's average media sentiment score of 0.39 beat Evolus' score of 0.00 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Aktis Oncology	Neutral
Evolus	Neutral

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 5.0% of Evolus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Evolus has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$6.50M	203.37	-$63.73M	-$0.38	N/A
Evolus	$297.18M	1.28	-$51.64M	-$0.67	N/A

Aktis Oncology has a net margin of 0.00% compared to Evolus' net margin of -14.39%.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Evolus	-14.39%	N/A	-19.03%

Summary

Aktis Oncology beats Evolus on 9 of the 15 factors compared between the two stocks.

Get Evolus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EOLS vs. The Competition

Export

Metric	Evolus	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$379.02M	$8.58B	$6.80B	$12.42B
Dividend Yield	N/A	2.48%	2.67%	9.39%
P/E Ratio	-8.59	15.41	27.05	24.17
Price / Sales	1.28	6.81	517.90	92.83
Price / Cash	N/A	18.55	26.68	47.25
Price / Book	-15.99	3.27	10.65	6.23
Net Income	-$51.64M	$230.22M	$3.59B	$331.42M
7 Day Performance	-8.21%	-1.52%	-0.84%	-1.22%
1 Month Performance	-13.20%	-1.78%	1.42%	-1.36%
1 Year Performance	-37.58%	-0.62%	24.75%	18.43%

Evolus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EOLS Evolus	1.6649 of 5 stars	$5.76 +3.7%	$16.00 +178.0%	-39.7%	$379.02M	$297.18M	N/A	170
SEPN Septerna	2.1701 of 5 stars	$32.21 -3.6%	$45.89 +42.5%	+156.7%	$1.51B	$45.95M	N/A	N/A
MLTX MoonLake Immunotherapeutics	2.9634 of 5 stars	$19.05 -3.2%	$24.21 +27.1%	-64.1%	$1.45B	N/A	N/A	2	Analyst Forecast
NNNN Anbio Biotechnology	0.2997 of 5 stars	$9.52 +0.3%	N/A	N/A	$1.37B	$8.65M	N/A	27	Gap Down
PAHC Phibro Animal Health	4.8301 of 5 stars	$33.05 -0.8%	$42.50 +28.6%	+12.4%	$1.35B	$1.50B	14.18	2,475	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EOLS) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evolus (EOLS) Competitors

EOLS vs. SEPN, MLTX, NNNN, PAHC, and AKTS

How does Evolus compare to Septerna?

Summary

How does Evolus compare to MoonLake Immunotherapeutics?

Summary

How does Evolus compare to Anbio Biotechnology?

Summary

How does Evolus compare to Phibro Animal Health?

Summary

How does Evolus compare to Aktis Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS vs. The Competition

Evolus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evolus (EOLS) Competitors

EOLS vs. SEPN, MLTX, NNNN, PAHC, and AKTS

How does Evolus compare to Septerna?

Do analysts recommend SEPN or EOLS?

Is SEPN or EOLS more profitable?

Which has more risk and volatility, SEPN or EOLS?

Do institutionals and insiders have more ownership in SEPN or EOLS?

Which has preferable valuation and earnings, SEPN or EOLS?

Does the media prefer SEPN or EOLS?

Summary

How does Evolus compare to MoonLake Immunotherapeutics?

Does the media refer more to MLTX or EOLS?

Which has preferable earnings and valuation, MLTX or EOLS?

Do analysts rate MLTX or EOLS?

Do institutionals & insiders believe in MLTX or EOLS?

Is MLTX or EOLS more profitable?

Which has more volatility & risk, MLTX or EOLS?

Summary

How does Evolus compare to Anbio Biotechnology?

Is NNNN or EOLS more profitable?

Do institutionals and insiders believe in NNNN or EOLS?

Do analysts recommend NNNN or EOLS?

Does the media refer more to NNNN or EOLS?

Which has stronger earnings & valuation, NNNN or EOLS?

Which has more risk and volatility, NNNN or EOLS?

Summary

How does Evolus compare to Phibro Animal Health?

Is PAHC or EOLS more profitable?

Which has more volatility & risk, PAHC or EOLS?

Do institutionals and insiders hold more shares of PAHC or EOLS?

Does the media refer more to PAHC or EOLS?

Which has better earnings & valuation, PAHC or EOLS?

Do analysts prefer PAHC or EOLS?

Summary

How does Evolus compare to Aktis Oncology?

Do analysts recommend AKTS or EOLS?

Does the media prefer AKTS or EOLS?

Do institutionals & insiders have more ownership in AKTS or EOLS?

Which has better earnings and valuation, AKTS or EOLS?

Is AKTS or EOLS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS vs. The Competition

Evolus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools